Zai Lab (ZLAB) Net Income towards Common Stockholders (2020 - 2026)
Zai Lab's (ZLAB) quarterly Net Income towards Common Stockholders came in at -$51.0 million in Q1 2026, down 5.32% year-on-year from -$53.9 million in Q1 2025, and down 1.2% quarter-over-quarter from -$50.4 million in Q4 2025.
Zai Lab (ZLAB) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Zai Lab has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$51.0 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$51.0 million, down 5.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$178.1 million (up 29.34% YoY), and the FY2025 annual result was -$175.5 million, up 31.73% from the prior year.
- Net Income towards Common Stockholders came in at -$51.0 million for Q1 2026 at Zai Lab, down from -$50.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$36.0 million in Q3 2025 to a low of -$161.2 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$61.8 million (2022), against an average of -$74.2 million.
- Peak annual rise in Net Income towards Common Stockholders reached 70.84% in 2022, while the deepest fall reached 67.19% in 2022.
- Zai Lab's Net Income towards Common Stockholders stood at -$61.8 million in 2022, then plunged by 54.49% to -$95.4 million in 2023, then climbed by 14.4% to -$81.7 million in 2024, then soared by 38.29% to -$50.4 million in 2025, then slipped by 1.2% to -$51.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$51.0 million (Q1 2026), -$50.4 million (Q4 2025), and -$36.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Zai Lab | 20.15 Bn | 20.05 Bn | 61.30 Mn | -51.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.02 Mn |
| Dec 31, 2025 | -50.41 Mn |
| Sep 30, 2025 | -35.96 Mn |
| Jun 30, 2025 | -40.73 Mn |
| Mar 31, 2025 | -48.44 Mn |
| Dec 31, 2024 | -81.68 Mn |
| Sep 30, 2024 | -41.67 Mn |
| Jun 30, 2024 | -80.28 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -95.43 Mn |
| Sep 30, 2023 | -69.15 Mn |
| Jun 30, 2023 | -120.90 Mn |
| Mar 31, 2023 | -49.14 Mn |
| Dec 31, 2022 | -61.77 Mn |
| Sep 30, 2022 | -161.19 Mn |
| Jun 30, 2022 | -137.93 Mn |
| Mar 31, 2022 | -82.39 Mn |
| Dec 31, 2021 | -211.83 Mn |
| Sep 30, 2021 | -96.41 Mn |
| Jun 30, 2021 | -163.32 Mn |